Pathogen Reduction Technologies: The Best Solution for Safer Blood?
Susanne Maria Picker*
University Hospital of Cologne, 65 Lippstadt, Germany
- Corresponding Author:
- Susanne Maria Picker
University Hospital of Cologne
65 Lippstadt, Germany
E-mail: [email protected]
Received Date: October 01, 2012; Accepted Date: October 22, 2012; Published Date: October 24, 2012
Citation: Picker SM (2012) Pathogen Reduction Technologies: The Best Solution for Safer Blood? J Blood Disord Transfus 3:133. doi: 10.4172/2155-9864.1000133
Copyright: © 2012 Picker SM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Although it is generally accepted that blood has never been safer than today, transfusion-associated side effects, particularly infective, still occur. Unlike screening strategies, pathogen reduction technologies offer a new approach to increase blood safety by actively/directly targeting possible, also emerging pathogens or donor leukocytes. Advanced technologies for cellular blood products like the psoralen-based INTERCEPT BLOOD SYSTEM or the riboflavin-based Mirasol pathogen reduction technology system have extensively been examined and are on the way to enter the blood bank routine. However, as with any medical treatment, the transfusion of pathogen reduced blood products is not completely risk-free. Due to possible impairment of the treated blood cells the transfusion success is significantly lower as compared to untreated blood products. Long-term side effects concerning the photosensitizers and their photoproducts still remain a matter of debate. This paper outlines current pathogen reduction technologies but also focuses on ethical concerns associated with the employment of these techniques.